Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer

Ihtzaz Ahmed Malik, Mansi Rajput, Rieke Werner, Dorothea Fey, Niloofar Salehzadeh, Christine A. F. von Arnim & Jörg Wilting
Abstract The incidence of primary liver tumors, hepatocellular carcinoma (HCC), intrahepatic cholangiocellular carcinoma (ICC), and combined HCC/ICC (cHCC/CC) is increasing. For ICC, targeted therapy exists only for a small subpopulation of patients, while for HCC, Sorafenib and Lenvatinib are in use. Diagnosis of cHCC/CC is a great challenge and its incidence is underestimated, bearing the risk of unintended non-treatment of ICC. Here, we investigated effects of targeted inhibitors on human ICC cell lines (HUH28, RBE,...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.